National Jewish Health Severe Asthma Symposium

National Jewish Health Severe Asthma Free CME Livestream Symposium

Join the session at https://bit.ly/Oct17SevereAsthma.

Where Are the New Targets in Severe Asthma? Looking Upstream in the Inflammatory Cascade

Sunday, October 17, 2021 •  Livestream 5:15 p.m. to 6:15 p.m. CST
Begins at 3:15 p.m. PST, 4:15 p.m. MST, 6:15 p.m. EST

For more Information: www.njhealth.org/AsthmaCHEST21

Program Faculty:
Eileen Wang, MD, MPH, Assistant Professor, Division of Allergy & Clinical Immunology, Department of Medicine, National Jewish Health, Denver, Colorado

Michael E. Wechsler, MD, MMSc, Director of The Cohen Family Asthma Institute, Professor of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, Colorado

Learning Objectives:
Upon completion of this activity, the participant will be better able to:
1. Define the epithelial alarmins and their pivotal role in inflammation in asthma.
2. Describe how the epithelial alarmins impact both T2 and non-T2 downstream inflammation in asthma.
3. Explain how therapies, such as anti-TSLP, would be expected to modulate airway inflammation in patients with either a T2-high or T2-low phenotype.
4. Evaluate the results of clinical trials of novel therapies that target the epithelial alarmins.

This educational activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.

Contact:
For questions, please call the Office of Professional Education at National Jewish Health at 303.398.1000 or 800.844.2305, or email proed@njhealth.org.

For more information: www.njhealth.org/AsthmaCHEST21